Jubilant Pharma

Jhunjhunwala Portfolio: This pharma stock has zoomed over 100% in 6 months

Shares of Jubilant Pharmova surged 12 per cent on the BSE in Friday's intra-day trade to hit a new high of Rs 1,169.55, in an otherwise subdued market.

Jubilant Pharmova hits all time high on receiving 'VAI' tag for US facility

Jubilant Pharmova share price rose as much as 4.2 per cent, touching its all time high at Rs 1060.15 per share on the BSE in early hours of Wednesday's intraday deals

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Jubilant Pharmova Q1 results: Net profit rises multi-fold to Rs 481.8 cr

Jubilant Pharmova Ltd on Friday reported a multi-fold jump in consolidated net profit to Rs 481.8 crore boosted by gain on sale on investment in associate firm SOFIE Biosciences Inc USA. The company had posted a consolidated net profit of Rs 6 crore a year earlier, Jubilant Pharmova said in a regulatory filing. Consolidated total revenue from operations stood at Rs 1,731.7 crore as against Rs 1,586.9 crore in the year-ago period, it added. The exceptional items in the first quarter of the current fiscal include net income of Rs 669.2 crore following sale of investment in SOFIE, expenses of Rs 91.6 crore accrued due to closure of manufacturing operations of solid dosage formulation facility at Salisbury, Maryland, USA; Rs 95.3 crore provision for slow moving inventory in respect of solid dosage formulation business and litigation cost of Rs 50 crore among others. During the quarter, Jubilant Pharmova said its radiopharmaceuticals segment revenue grew 28 per cent year-on-year to Rs 2

Jubilant Pharmova Q4 results: Consolidated net loss narrows to Rs 5.86 cr

Revenue from segments that make copycat drugs and medicines used for allergy immunotherapy rose 0.8% and 14%, respectively, during the quarter

Nifty SmallCap up 16% in 1 month; key levels to watch on overbought stocks

Apar Industries, CESC, Glenmark, Jubilant Pharma and Power India are trading in overbought zone; charts suggest bias to remain positive as long as these support levels hold.

Jubilant Pharma to sell stake in Sofie Biosciences for $139.43 million

Jubilant Pharma had invested $25 million in Sofie Biosciences in November 2020 and now plans to exit its investment completely

Jubilant Pharmova's Q1 consolidated net profit dips 87% at Rs 6 cr

Jubilant Pharmova Ltd on Wednesday reported an 87 per cent decline in consolidated net profit at Rs 6 crore in the first quarter ended June 30, impacted by higher expenses. The company had posted a consolidated net profit of Rs 46.8 crore in the same period last fiscal, Jubilant Pharmova said in a regulatory filing. Consolidated total revenue from operations were at Rs 1,586.9 crore, as compared to Rs 1,451.7 crore in the year-ago period, it added. Total expenses in the first quarter were at Rs 1,568.9 crore, as compared to Rs 1,393.8 crore in the corresponding period a year ago. Among various segments, Jubilant Pharmova said the radiopharmaceuticals vertical clocked a revenue of Rs 204 crore in the first quarter, while the radiopharmacies registered Rs 487 crore revenue. The generics business had a revenue of Rs 202 crore and the contract development and manufacturing organisation (CDMO) API segment had posted revenue of Rs 177 crore.

Jubilant Pharmova slips 11% on USFDA observation, weak Q4 results

The United States Food and Drug Administration (US FDA) has classified its inspection of the company's Montreal Canada contract manufacturing (CMO) facility as Official Action Indicated (OAI)

Fitch downgrades Jubilant Pharma to "BB-" indicating higher default risk

Rating agency foresees firm's financial leverage worsening as a rise in capex will coincide with lower profitability

Jubilant Pharma arm to raise $400 mn from Standard Chartered to repay debt

While the term loan and bonds aggregate to USD 350 million, about Rs 2,787 crore, the company is raising another tranche of USD 50 million (about Rs 400 crore) for capital expenditure.

Jubilant Pharmova posts Q1 consolidated net profit of Rs 160 crore

Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 160.49 crore from continuing operations for the quarter ended June 30, 2021. The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing. Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added. Figures for the quarter are not comparable with previous periods since the Life Science Ingredients business was demerged with effect from February 1, 2021 pursuant to the composite scheme of arrangement during the previous year, the filing said. "During this quarter, in addition to YoY increase, we also reported sequential improvement in the specialty pharma segment with gradual recovery across radiopharmaceuticals, radiopharmacy and allergy business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said in a ...

Aurobindo, Zydus, Jubilant, others recall various products in US market

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

Jubilant Pharma gets USFDA nod for generic hypertension drug

Company's product is a generic version of Daiichi Sankyo's Azor

Jubilant Pharma raises $300 million via bonds

Shares of Jubilant Life Sciences were trading 1.89 per cent higher at Rs 601 on BSE